ALSO NOTED: Does FDA scrutinize new generics enough?; BMS shops baby-food business;

> Are generics as good as brand-name drugs? The Los Angeles Times questions the FDA's generic-approval process, which leans lightly on drug makers. Report

> Bristol-Myers Squibb is looking to get out of the baby food business, scouting out potential buyers for the $7 billion to $9 billion unit. Report

> Potential buyers have been touring Pfizer's Ann Arbor, MI, facility, which is set to close in 2009. Report

> India's Sun Pharmaceutical Industries got FDA approval for its copycat form of AstraZeneca's Ethyol, used to reduce kidney damage in patients with advanced ovarian cancer. Report

> Teva is planning an aggressive move into biogenerics. Report

> In an interview, Celgene CEO Sol Barer laid out some of the basics in how it will integrate operations with Pharmion, a biotech Celgene paid $2.9 billion for. Report

And Finally... A new book takes Big Pharma to task for marketing tactics. Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.